NDA 213182 · Novo Nordisk INC
Rybelsus
Semaglutide · Oral
Last checked: Nov 20, 2026Latest source record: Jan 16, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jan 16, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
626
187 Phase 3, 161 recruiting
FAERS reports
7,735
4,368 serious, 180 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 16, 2020 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval LabelMedication GuideLetter
2 products under this application
- RYBELSUS · SEMAGLUTIDE 3MG · TABLET, ORAL · Prescription
- RYBELSUS · SEMAGLUTIDE 7MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Semaglutide" as an intervention, any sponsor and status, largest first.
- A Study of Cardiovascular Events iN Diabetes PlusPivotal-lookingActive, not recruiting
University of OxfordAcademic, hospital or other
NCT05441267 · 21,296 participants · Start Mar 13, 2023 · Primary completion Aug 17, 2028
Drug: Semaglutide Oral Tablet; Placebo oral tablet · For: Diabetes Mellitus, Type 2
Sites: Oxford, United Kingdom
- Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03574597 · 17,604 participants · Start Oct 24, 2018 · Primary completion Jun 21, 2023
Drug: Semaglutide; Placebo (semaglutide) · For: Overweight; Obesity
Sites: Birmingham, Alabama; Montgomery, Alabama; Glendale, Arizona · 833 sites in all
- A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03914326 · 9,651 participants · Start Jun 17, 2019 · Primary completion Aug 23, 2024
Drug: Semaglutide; Placebo (semaglutide) · For: Diabetes Mellitus, Type 2
Sites: Montgomery, Alabama; Little Rock, Arkansas; Searcy, Arkansas · 492 sites in all
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05669755 · 7,101 participants · Start Mar 1, 2023 · Primary completion Sep 1, 2027
Drug: Cagrilintide; Semaglutide and 1 more · For: Cardiovascular Disease
Sites: Birmingham, Alabama; Montgomery, Alabama; Scottsdale, Arizona · 633 sites in all
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05390892 · 6,000 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 1, 2029
Drug: SGLT2 inhibitor; GLP-1 receptor agonist · For: Type2Diabetes; ASCVD
Sites: Huntsville, Alabama; Scottsdale, Arizona; Los Angeles, California · 36 sites in all
- A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney DiseasePivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03819153 · 3,533 participants · Start Jun 17, 2019 · Primary completion Jan 9, 2024
Drug: Semaglutide; Placebo (semaglutide) · For: Diabetes Mellitus, Type 2
Sites: Tuscumbia, Alabama; Chula Vista, California; Concord, California · 413 sites in all
- A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05567796 · 3,400 participants (planned) · Start Nov 1, 2022 · Primary completion Oct 30, 2024
Drug: Cagrilintide; Semaglutide and 2 more · For: Obesity
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 256 sites in all
- Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01720446 · 3,297 participants · Start Feb 21, 2013 · Primary completion Mar 15, 2016
Drug: semaglutide; semaglutide and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Chandler, Arizona; Anaheim, California · 253 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea1,110
- vomiting769
- diarrhoea614
- off label use484
- decreased appetite465
- constipation443
- blood glucose increased372
- weight decreased365
- impaired gastric emptying345
- headache325
- fatigue313
- dizziness305
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 7 |
| 2020 | 487 |
| 2021 | 841 |
| 2022 | 1,038 |
| 2023 | 1,065 |
| 2024 | 1,519 |
| 2025 | 1,570 |
| 2026 | 1,203 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rybelsus (Semaglutide)
2024 spending
$1.89B
Beneficiaries
309,993
1,251,733 claims
Per beneficiary
$6,097
$30.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $73,444,409 |
| 2021 | $454,563,823 |
| 2022 | $974,894,470 |
| 2023 | $1,665,906,943 |
| 2024 | $1,890,082,026 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
Wharton S, Lingvay I, Bogdanski P, et al. · N Engl J Med 2025 · Clinical Trial, Phase II, Multicenter Study
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, Horn DB, le Roux CW, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Yao H, Zhang A, Li D, et al. · BMJ 2024 · Systematic Review, Network Meta-Analysis
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M, Færch L, Jeppesen OK, et al. · Lancet 2021 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Tan HC, Dampil OA, Marquez MM · J ASEAN Fed Endocr Soc 2022 · Meta-Analysis, Systematic Review
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Wadden TA, Bailey TS, Billings LK, et al. · JAMA 2021 · Clinical Trial, Phase III, Comparative Study
Sponsor: Novo Nordisk
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.